Blockchain Registration Transaction Record

ABVC BioPharma Secures Patent Approval for ADHD Treatment in Taiwan

ABVC BioPharma secures patent approval in Taiwan for Polygala Extract to treat ADHD, reinforcing its global intellectual property portfolio. The company's innovative treatment targets ADHD core symptoms through Norepinephrine Transporter inhibition, with plans to expand globally and improve outcomes for patients worldwide.

This news matters as ABVC BioPharma's innovative treatment for ADHD has the potential to significantly impact the global ADHD treatment market, which is projected to reach $32.14 billion by 2030. The approval of this patent marks a milestone in the company's commitment to advancing ADHD care and providing a novel therapeutic option for patients inadequately managed by existing therapies.